{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:09:51Z","timestamp":1759536591006,"version":"build-2065373602"},"reference-count":6,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1053\/j.ajkd.2016.04.001","type":"journal-article","created":{"date-parts":[[2016,5,19]],"date-time":"2016-05-19T15:47:19Z","timestamp":1463672839000},"page":"990-991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Reply to \u2018Febuxostat for Asymptomatic Hyperuricemia in CKD' and \u2018Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia\u2019"],"prefix":"10.1053","volume":"67","author":[{"given":"Dipankar","family":"Sircar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.ajkd.2016.04.001_bib1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.ajkd.2015.09.035","article-title":"Febuxostat for asymptomatic hyperuricemia in CKD","volume":"67","author":"Mome","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2016.04.001_bib2","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2016.04.001_bib3","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2016.04.001_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/bmj.319.7203.185","article-title":"Baseline imbalance in randomised controlled trials","volume":"319","author":"Roberts","year":"1999","journal-title":"BMJ"},{"issue":"6","key":"10.1053\/j.ajkd.2016.04.001_bib5","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","article-title":"Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial","volume":"66","author":"Sircar","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2016.04.001_bib6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.ajkd.2015.09.034","article-title":"Febuxostat renoprotection in CKD patients with asymptomatic hyperuricemia","volume":"67","author":"Filiopoulos","year":"2016","journal-title":"Am J Kidney Dis"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638616300166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638616300166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:51:17Z","timestamp":1759459877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638616300166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0272638616300166"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2016.04.001","relation":{},"ISSN":["0272-6386"],"issn-type":[{"type":"print","value":"0272-6386"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Reply to \u2018Febuxostat for Asymptomatic Hyperuricemia in CKD' and \u2018Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia\u2019","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2016.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.09.034","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.09.035","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}